PTC Therapeutics マネジメント
マネジメント 基準チェック /34
PTC Therapeuticsの CEO はMatt Kleinで、 Mar2023年に任命され、 の在任期間は 3.17年です。 の年間総報酬は$ 23.27Mで、 4.1%給与と95.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.15%を直接所有しており、その価値は$ 8.15M 。経営陣と取締役会の平均在任期間はそれぞれ6.5年と7.4年です。
主要情報
Matt Klein
最高経営責任者
US$23.3m
報酬総額
| CEO給与比率 | 4.12% |
| CEO在任期間 | 3.2yrs |
| CEOの所有権 | 0.2% |
| 経営陣の平均在職期間 | 6.5yrs |
| 取締役会の平均在任期間 | 7.4yrs |
経営陣の近況
Recent updates
PTCT: Early Neurology Launch And Pipeline Progress Will Support Bullish 2026 Outlook
Analysts have nudged their average price target for PTC Therapeutics higher to about $88 from roughly $86.50. This reflects updates to models after recent Q4 commentary, revised views on revenue trends, margin expectations, and future P/E assumptions.PTCT: Early Neurology Launch Execution Will Drive Bullish 2026 Outlook
Narrative Update on PTC Therapeutics The analyst price target for PTC Therapeutics has been trimmed from $87.93 to $86.50 as analysts balance generally higher Street targets and improved profit margin assumptions with slightly softer revenue growth expectations and a more conservative future P/E. Analyst Commentary Recent research updates on PTC Therapeutics show a mix of optimism and caution, with several analysts adjusting price targets after the Q4 report, Sephience launch updates, and broader sector views.
PTCT: Future Earnings Power Will Be Driven By Growing PKU And Huntington’s Pipelines
Analysts have raised PTC Therapeutics' consensus price target from the low $90s to around $120, citing updated Q4 results, early Sephience traction, and expectations that newer revenue streams could offset pressure in the DMD franchise. Analyst Commentary Recent research on PTC Therapeutics has leaned constructive, with several bullish analysts tying higher valuation ranges to execution around Sephience, updated Q4 commentary, and the broader revenue mix.PTCT: Future Earnings Power Will Be Driven By Expanding PKU And Huntington’s Franchises
The analyst price target for PTC Therapeutics has been raised by $6.61, with analysts pointing to stronger modeled revenue growth, higher profit margins, and updated P/E assumptions following recent Q4 commentary and comparative advantages in Huntington's disease treatments. Analyst Commentary Recent Street research around PTC Therapeutics has been broadly constructive, with several bullish analysts adjusting their models after the Q4 update and early Sephience launch commentary.PTC Therapeutics: Sephience As A Major Growth Driver
Feb 23PTCT: Sephience Execution Will Drive Bullish 2026 Outlook Despite DMD Pressure
Narrative Update: PTC Therapeutics The analyst price target for PTC Therapeutics has shifted modestly lower to align with our updated fair value of about $87.93, as analysts weigh mixed revisions to revenue growth and profitability assumptions against ongoing support from Sephience-driven estimates. Analyst Commentary Recent Street research on PTC Therapeutics centers on how Sephience trends could influence the company’s revenue mix, profitability path, and valuation, especially as the DMD franchise faces pressure.PTCT: Index Additions And Pipeline Execution Will Shape Bullish 2026 Outlook
Analysts have raised their fair value estimate for PTC Therapeutics to about $88.50 from $81.86, reflecting updated views on the discount rate, revenue trends, profit expectations, and a higher assumed future P/E that aligns with recent price target increases from several research firms. Analyst Commentary Recent Street research on PTC Therapeutics has focused on price target adjustments and rating changes, which feed directly into how analysts think about valuation, execution risk, and potential growth opportunities.
PTCT: Single-Drug Dependence Will Likely Limit Upside Despite Strong Launch Start
Narrative Update: PTC Therapeutics (PTCT) The analyst price target for PTC Therapeutics is updated in line with a series of upward Street revisions, as analysts point to stronger than expected Sephience launch metrics and recent Q3 outperformance, along with generally supportive views on small to mid cap biotech heading into 2026. Analyst Commentary Street research on PTC Therapeutics has leaned positive around the Q3 report and the Sephience launch, with several large firms lifting price targets after what they describe as strong initial commercial execution.PTCT: Future Earnings Power Will Be Driven By Expanding PKU Franchise
The analyst price target for PTC Therapeutics has been raised from about $103 to about $115. Analysts cited stronger Sephience launch trends, a shift in the modeled profit margin to 34%, a more moderate future P/E near 20x, and a less conservative revenue outlook as key drivers of the change.PTCT Overreliance On Single Drug Will Likely Cap Share Price Upside
The analyst fair value estimate for PTC Therapeutics has been raised from $44.00 to $55.00 per share as analysts factor in stronger than expected Sephience launch metrics, upwardly revised price targets across the Street, and improving confidence in the durability of the company’s growth trajectory. Analyst Commentary Recent Street research has broadly welcomed PTC Therapeutics Q3 performance and the stronger than expected Sephience launch, with several major firms lifting their price targets.PTCT: Launch Momentum And Index Additions Will Shape 2025 Outlook
The analyst price target for PTC Therapeutics has been raised by about $1.36 to roughly $81.86, as analysts highlight stronger than expected Sephience launch metrics, improving revenue and margin assumptions, and sustained post earnings momentum. Analyst Commentary Analysts are broadly constructive on PTC Therapeutics following its latest earnings, citing Sephience outperformance and improving visibility into the company’s growth trajectory.PTCT: Revenue Outlook And New Launch Performance Will Influence 2025 Assessment
Analysts have raised their price target for PTC Therapeutics from approximately $77.93 to $80.50, citing stronger-than-expected Sephience sales and continued momentum following the company's latest earnings report. Analyst Commentary Recent reports from Wall Street analysts reflect a range of views regarding PTC Therapeutics' execution and growth prospects, primarily driven by the company's strong recent earnings and the launch of Sephience.PTCT: Revenue Guidance Narrowing And Launch Momentum Will Shape 2025 Outlook
The analyst price target for PTC Therapeutics has been raised by $10, as analysts cite stronger-than-expected Sephience sales and increasing momentum following the company's recent earnings beat. Analyst Commentary Recent analyst reports on PTC Therapeutics highlight a wide range of perspectives following the company’s robust third-quarter results and new product launches.Upcoming Launches Will Drive Rare Disease Momentum Despite Ongoing Regulatory Risks
Analysts have increased their average price target for PTC Therapeutics by approximately $1.25 to $67.93. They cite heightened community interest in Sephience, improved profit margin forecasts, and overall strong sentiment for upcoming launches, despite recent regulatory setbacks.PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Shares Bounce 26% But Its Business Still Trails The Industry
Sep 08
Broad Approvals Will Elevate Rare Disease Markets Despite Setbacks
Analysts lowered their price targets for PTC Therapeutics following the FDA's Complete Response Letter for vatiquinone, citing the removal of Friedreich's ataxia revenues and increased regulatory uncertainty, though encouraging early signals from the Sephience launch and its broad approval label partially offset downside, resulting in a modest consensus target reduction from $68.31 to $66.69. Analyst Commentary Bullish analysts highlight the recent selloff post-FDA Complete Response Letter (CRL) for vatiquinone in Friedreich's ataxia as a buying opportunity, believing negative outcomes were anticipated and already priced into shares.Solid Earnings Reflect PTC Therapeutics' (NASDAQ:PTCT) Strength As A Business
May 13
2025 Approvals Of Sepiapterin And Vatiquinone Will Meet Unmet Medical Needs
Multiple anticipated regulatory approvals and successful product launches are expected to significantly boost PTC Therapeutics' revenues.PTC Therapeutics: Upside In Rare Disease Innovation
Mar 09PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts
Nov 29CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Dec 31 2025 | US$23m | US$959k | US$683m |
| Sep 30 2025 | n/a | n/a | US$752m |
| Jun 30 2025 | n/a | n/a | US$629m |
| Mar 31 2025 | n/a | n/a | US$595m |
| Dec 31 2024 | US$7m | US$882k | -US$363m |
| Sep 30 2024 | n/a | n/a | -US$453m |
| Jun 30 2024 | n/a | n/a | -US$480m |
| Mar 31 2024 | n/a | n/a | -US$579m |
| Dec 31 2023 | US$9m | US$747k | -US$627m |
| Sep 30 2023 | n/a | n/a | -US$642m |
| Jun 30 2023 | n/a | n/a | -US$618m |
| Mar 31 2023 | n/a | n/a | -US$571m |
| Dec 31 2022 | US$5m | US$598k | -US$559m |
報酬と市場: Mattの 総報酬 ($USD 23.27M ) は、 US市場 ($USD 8.73M ) の同規模の企業の平均を上回っています。
報酬と収益: Mattの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Matt Klein (52 yo)
3.2yrs
在職期間
US$23,266,326
報酬
Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, is Trustee of BioNJ Inc. Dr. Klein serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Ind...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 3.2yrs | US$23.27m | 0.15% $ 8.2m | |
| Co-Founder & Independent Director | 28.3yrs | US$547.41k | 0.018% $ 984.7k | |
| Chief Financial Officer | 2.8yrs | US$3.55m | 0.034% $ 1.8m | |
| Chief Technical Operations Officer | 7.4yrs | US$3.16m | 0.019% $ 1.0m | |
| Chief Business Officer | 11.1yrs | US$3.56m | 0.030% $ 1.6m | |
| Executive VP & Chief Medical Officer | 6yrs | US$3.27m | 0.034% $ 1.9m | |
| Senior VP | 6.9yrs | US$1.70m | 0.048% $ 2.6m | |
| Senior VP & Chief Information Officer | 1.6yrs | データなし | データなし | |
| Head of Investor Relations | no data | データなし | データなし | |
| Executive VP & Chief Legal Officer | 14.2yrs | US$2.19m | 0.13% $ 6.9m | |
| Vice President of Corporate Communications | no data | データなし | データなし | |
| Chief Human Resources Officer | 5.6yrs | データなし | データなし |
6.5yrs
平均在職期間
57.5yo
平均年齢
経験豊富な経営陣: PTCTの経営陣は経験豊富で経験豊富です（平均在職期間は6.5年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 3.2yrs | US$23.27m | 0.15% $ 8.2m | |
| Co-Founder & Independent Director | 28.3yrs | US$547.41k | 0.018% $ 984.7k | |
| Independent Chairman of the Board | 24.8yrs | US$896.31k | 1.85% $ 100.1m | |
| Independent Director | 20.4yrs | US$494.41k | 0.018% $ 945.8k | |
| Independent Director | 13.7yrs | US$463.91k | 0.019% $ 1.1m | |
| Independent Director | 7.4yrs | US$507.41k | 0.0080% $ 434.3k | |
| Independent Director | 10.9yrs | US$477.41k | 0.019% $ 1.1m | |
| Director | less than a year | データなし | データなし | |
| Independent Director | 3.9yrs | US$475.91k | 0.018% $ 959.9k | |
| Independent Director | 7.4yrs | US$471.91k | 0.0068% $ 368.9k | |
| Independent Director | 4.9yrs | US$479.41k | 0.019% $ 1.0m |
7.4yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: PTCTの 取締役会 は 経験豊富 であると考えられます ( 7.4年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/03 14:28 |
| 終値 | 2026/05/01 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
PTC Therapeutics, Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。35
| アナリスト | 機関 |
|---|---|
| Luke Herrmann | Baird |
| Joel Beatty | Baird |
| null null | Baird |